End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.75 CNY | +1.08% | +3.90% | -21.01% |
Apr. 25 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.01% | 7.91B | B- | ||
+16.62% | 70.95B | C+ | ||
+2.99% | 25.25B | C+ | ||
+5.62% | 8.67B | C | ||
+6.46% | 8.16B | B | ||
-0.61% | 4.51B | B- | ||
+17.12% | 4.31B | B+ | ||
-0.14% | 4.07B | B- | ||
-3.30% | 3.84B | B | ||
+21.70% | 3.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000963 Stock
- Ratings Huadong Medicine Co., Ltd